Less than $10/month! Screen on your Watchlists and Portfolios with Barchart Plus. FREE 30 Day Trial
or

Amgen Inc (AMGN)

Amgen Inc (AMGN)
297.94 x 1 298.55 x 1
Post-market by (Cboe BZX)
297.93 +3.66 (+1.24%) 02/20/25 [NASDAQ]
297.94 x 1 298.55 x 1
Post-market 298.01 +0.08 (+0.03%) 17:37 ET
Quote Overview for Thu, Feb 20th, 2025
Watch
    Add or delete the symbol from one or more Watchlists.
Day Low
293.93
Day High
298.13
Open 294.67
Previous Close 294.27 294.27
Volume 2,319,200 2,319,200
Avg Vol 3,061,800 3,061,800
Stochastic %K 49.34% 49.34%
Weighted Alpha +1.95 +1.95
5-Day Change +2.87 (+0.97%) +2.87 (+0.97%)
52-Week Range 253.30 - 346.85 253.30 - 346.85
  • 1D
  • 5D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
  • MAX
Full Chart
  • OHLC Bars
  • Colored OHLC Bars
  • HLC Bars
  • Candlestick Hollow
  • Candlestick Open-to-Close
  • Candlestick Close-to-Close
  • Heikin-Ashi
  • Line Chart
  • Area Chart
  • Renko
  • Column
  • Baseline
  • Line Break
  • Range
  • Kagi
  • Point And Figure
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 160,049,488
  • Shares Outstanding, K 537,205
  • Annual Sales, $ 33,424 M
  • Annual Income, $ 4,090 M
  • EBIT $ 7,258 M
  • EBITDA $ 11,329 M
  • 60-Month Beta 0.56
  • Price/Sales 4.73
  • Price/Cash Flow 13.70
  • Price/Book 26.78

Options Overview Details

View History
  • Implied Volatility 18.97% ( -0.33%)
  • Historical Volatility 26.40%
  • IV Percentile 2%
  • IV Rank 2.27%
  • IV High 55.92% on 11/20/24
  • IV Low 18.11% on 05/21/24
  • Put/Call Vol Ratio 0.62
  • Today's Volume 5,690
  • Volume Avg (30-Day) 17,882
  • Put/Call OI Ratio 0.75
  • Today's Open Interest 179,709
  • Open Int (30-Day) 158,894

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 30 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/25
See More
  • Average Estimate 4.21
  • Number of Estimates 12
  • High Estimate 4.84
  • Low Estimate 3.89
  • Prior Year 3.96
  • Growth Rate Est. (year over year) +6.31%

Price Performance

See More
Period Period Low Period High Performance
1-Month
270.28 +10.23%
on 01/21/25
Period Open: 272.11
309.49 -3.74%
on 02/06/25
+25.82 (+9.49%)
since 01/17/25
3-Month
253.30 +17.62%
on 12/19/24
Period Open: 287.87
309.49 -3.74%
on 02/06/25
+10.06 (+3.49%)
since 11/20/24
52-Week
253.30 +17.62%
on 12/19/24
Period Open: 283.51
346.85 -14.10%
on 07/25/24
+14.42 (+5.09%)
since 02/20/24

Most Recent Stories

More News
J&J Stock Up More Than 6% in a Month: Time to Buy, Sell or Hold?

J&J JNJ stock has risen more than 6% in the past month. The reason behind the increase was a strong-than-expected fourth-quarter earnings report and an optimistic outlook for the Innovative Medicine segment...

ITCI : 128.54 (-0.05%)
JNJ : 159.68 (+1.13%)
KVUE : 22.39 (+0.54%)
AMGN : 297.93 (+1.24%)
Wall Street Predicts This Dividend Stock to Soar 31%: Should You Buy The Dip Now?

Amgen stock is an attractive buy on the dip for passive income-focused investors.

NVO : 83.74 (+0.41%)
LLY : 873.12 (+0.70%)
AMGN : 297.93 (+1.24%)
Gilead Sciences (GILD) Q4 Earnings: What To Expect

Gilead Sciences (GILD) Q4 Earnings: What To Expect

GILD : 110.03 (+2.21%)
ABBV : 200.88 (+1.79%)
AMGN : 297.93 (+1.24%)
Investing $1,000 in These 3 Beaten-Down Stocks Could Be a Brilliant Move

Investing in stocks that aren't performing well can be a good move, but only if there are good reasons to think they will recover. That isn't the case for many companies that have lagged broader equities....

CRSP : 50.43 (-4.88%)
REGN : 696.02 (+1.51%)
AMGN : 297.93 (+1.24%)
3 Fabulous Dividend Stocks to Buy in February

February is the shortest month, but that doesn't mean income investors don't have much time to find great stocks. Three Motley Fool contributors believe they have identified fabulous dividend stocks to...

ABT : 133.17 (+0.79%)
ABBV : 200.88 (+1.79%)
GILD : 110.03 (+2.21%)
AMGN : 297.93 (+1.24%)
Vertex Pharmaceuticals (VRTX) Q4 Earnings Report Preview: What To Look For

Vertex Pharmaceuticals (VRTX) Q4 Earnings Report Preview: What To Look For

VRTX : 480.33 (+1.82%)
ABBV : 200.88 (+1.79%)
AMGN : 297.93 (+1.24%)
We Asked Retail Traders About Eli Lilly’s Biggest Post-Q4 Risk — Most Say It’s The Weight-Loss Drug Wars

Lilly’s fiercest competitor in the obesity market is Novo Nordisk, which offers Ozempic and Wegovy. However, rising threats from other players such as Hims & Hers, Amgen, and Viking Therapeutics also...

VKTX : 31.63 (-2.04%)
NVO : 83.74 (+0.41%)
HIMS : 66.41 (-3.39%)
LLY : 873.12 (+0.70%)
AMGN : 297.93 (+1.24%)
Stock market today: Wall Street finishes mixed as strong fashion, tobacco stocks offset Ford's drop

Wall Street drifted through a mixed day of trading as rising fashion and cigarette stocks worked against drops for Ford Motor and Qualcomm

AA : 37.25 (+2.96%)
GOOGL : 184.56 (-0.38%)
MAT : 21.80 (+0.09%)
$SPX : 6,117.52 (-0.43%)
F : 9.39 (+0.54%)
HON : 211.35 (+0.26%)
AMGN : 297.93 (+1.24%)
$IUXX : 22,068.06 (-0.48%)
HSY : 166.10 (+1.34%)
QCOM : 173.70 (-0.87%)
AMD : 114.17 (-0.45%)
$DOWI : 44,176.65 (-1.01%)
AZN Q4 Earnings Lag, Sales Beat, Stock Up on China Probe Update

AstraZeneca’s AZN fourth-quarter 2024 core earnings of $1.05 per American depositary share (“ADS”) missed the Zacks Consensus Estimate of $1.07. Core earnings of $2.09 per share rose 44% year over...

AZN : 74.56 (+1.02%)
MRK : 87.68 (+2.43%)
AMGN : 297.93 (+1.24%)
SNY : 54.13 (+0.99%)
Stocks Muted Before the Open With Focus on U.S. Economic Data and Amazon Earnings

March S&P 500 E-Mini futures (ESH25) are up +0.05%, and March Nasdaq 100 E-Mini futures (NQH25) are down -0.08% this morning as investors awaited a new round of U.S. economic data, remarks from Federal...

NVDA : 140.11 (+0.63%)
GOOGL : 184.56 (-0.38%)
MAERB.C.DX : 12,625.000 (+1.28%)
HON : 211.35 (+0.26%)
F : 9.39 (+0.54%)
SWKS : 67.32 (-0.44%)
AMGN : 297.93 (+1.24%)
ESH25 : 6,137.00 (+0.01%)
BMY : 55.79 (+1.47%)
JCI : 88.83 (-1.79%)
FTNT : 114.21 (-0.31%)
QCOM : 173.70 (-0.87%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 24% Sell with a Weakening short term outlook on maintaining the current direction.

See More Share

Business Summary

Amgen Inc. is the leading biotech companies world wide, with a strong presence in the oncology/hematology, cardiovascular disease, neuroscience, inflammation, bone health & nephrology and neuroscience markets. It developed two most successful drugs, Epogen & Neupogen. Amgen successfully launched two...

See More

Key Turning Points

3rd Resistance Point 303.60
2nd Resistance Point 300.86
1st Resistance Point 299.40
Last Price 297.93
1st Support Level 295.20
2nd Support Level 292.46
3rd Support Level 291.00

See More

52-Week High 346.85
Fibonacci 61.8% 311.11
Fibonacci 50% 300.08
Last Price 297.93
Fibonacci 38.2% 289.04
52-Week Low 253.30

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar

Mastering Fibonacci: The Hidden Order in Market Movements